Abstracts Archive - Page 2383 of 2607 - ACR Meeting Abstracts

Abstract Number: 744 • 2013 ACR/ARHP Annual Meeting
Relationship Between Infectious Side Effects and Immunoglobulin Levels In The Maintenance Rituximab Vs Azathioprine For ANCA-Associated Vasculitides Trial
Loic Guillevin¹, Christian Pagnoux², Alexandre Karras³, Chahera Khouatra⁴, Olivier Aumaître⁵, Pascal Cohen⁶, Olivier Decaux⁷, Hélène Desmurs-Clavel⁸, Pierre Gobert⁹, Thomas Quemeneur¹⁰, Claire Blanchard-Delaunay¹¹, Pascal Godmer¹², Xavier Puechal¹³, Pierre-Louis Carron¹⁴, Pierre-Yves Hatron¹⁵, Nicolas Limal¹⁶, Mohamed Hamidou¹⁷, Francois Maurier¹⁸, Thomas Papo¹⁹, Matthias Büchler²⁰, Bernard Bonnotte²¹, Philippe Ravaud²² and Luc Mouthon²³, ¹Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ²Internal Medicine, Hôpital Cochin, PARIS, France, ³Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁴CHU Lyon, Lyon, France, ⁵Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁷Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁸University of Lyon, LYON, France, ⁹Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹⁰Internal medicine, CHR de Valenciennes, Valenciennes, France, ¹¹Internal Medicine, Hôpital de Niort, Niort, France, ¹²Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ¹³Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹⁴Internal Medicine, Centre Hospitalier de Grenoble, Grenoble, France, ¹⁵Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹⁶Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, ¹⁷Internal Medicine Department, Nantes University Hospital, Nantes, France, ¹⁸HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ¹⁹Internal Medicine, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, ²⁰Nephrology, University Hospital of Tours, TOURS, France, ²¹Department of Internal Medicine, Centre Hospitalier de Dijon, Dijon, France, ²²Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ²³Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: MAINRITSAN trial (NCT 00748644) results demonstrated that 500 mg of rituximab (RTX) every 6 months was superior to azathioprine (AZA) to maintain ANCA-associated–vasculitis (AAV)…
Abstract Number: 745 • 2013 ACR/ARHP Annual Meeting
Rate Of Infection and Development Of Malignancy In Patients With ANCA-Associated Vasculitis Treated With Rituximab: A Meta-Analysis From Randomized Trials
Carolina Mejia-Otero¹, Carlos J. Lozada² and Luis Arias-Urdaneta³, ¹Internal Medicine, Mount Sinai Medical Center, Miami, FL, ²Dept of Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ³Rheumatology, Mount Sinai Medical Center, Miami Beach, FL
Background/Purpose: Over the past 40 years failures to achieve remission in a proportion of patients and the potential development of significant adverse effects have been…
Abstract Number: 746 • 2013 ACR/ARHP Annual Meeting
Glucocorticoid Treatment and Damage In The Antineutrophil- Cytoplasm Antibody Associated Vasculitides
Joanna Robson¹, Helen Doll², Ravi Suppiah³, Oliver Flossmann⁴, Lorraine Harper⁵, Peter Hoglund⁶, David Jayne⁷, Alfred Mahr⁸, Kerstin Westman⁹ and Raashid A. Luqmani¹⁰, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ²Department of Population Health, University of East Anglia, Norwich, United Kingdom, ³Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁴Nephrology, Royal Berkshire Hospital, Reading, United Kingdom, ⁵Nephrology, University of Birmingham, Birmingham, United Kingdom, ⁶Competence Centre fo Clinical Research, Skane University Hospital, Lund, Sweden, ⁷Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ⁸Department of Internal Medicine, Hospital Saint-Louis, Paris, France, ⁹Nephrology and Transplantation, Skåne University Hospital Malmö, Lund University, Malmö, Sweden, ¹⁰Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom
Background/Purpose: Granulomatosis with polyangiitis [Wegener's] (GPA) and microscopic polyangiitis (MPA) are antineutrophil-cytoplasm antibody associated vasculitides (AAVs). Damage is quantified by the Vasculitis Damage Index (VDI).…
Abstract Number: 747 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Glucocorticoids To Treat Limited Flares In ANCA-Associated Vasculitis
Eli Miloslavsky¹, Ulrich Specks², Peter A. Merkel³, Philip Seo⁴, Robert F. Spiera⁵, Carol A. Langford⁶, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, E. William St. Clair⁹, Nadia Tchao¹⁰, Linna Ding¹¹, David Ikle¹², Brett Jepson¹², Paul Brunetta¹³ and John H. Stone¹⁴, ¹Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, ²Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁷Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁹Medicine, Duke University Medical Center, Durham, NC, ¹⁰Immune Tolerance Network, Bethesda, MD, ¹¹NIAID, Bethesda, MD, ¹²Rho, Chapel Hill, NC, ¹³Biotherapeutics, Genentech, So San Francisco, CA, ¹⁴Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose: The great majority of patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) achieve disease remission initially, but relapses occur in up to…
Abstract Number: 715 • 2013 ACR/ARHP Annual Meeting
Protein Phosphatase 5 (PP5) Regulates Methylation Sensitive Gene Expression In CD4+ T Cells
Dipak R. Patel, Gabriela Gorelik and Bruce C. Richardson, Internal Medicine, University of Michigan, Ann Arbor, MI
Background/Purpose: CD4+CD28- T cells are enriched in chronic inflammatory diseases like rheumatoid arthritis (RA) and lupus. They are cytotoxic and resistant to apoptosis. Compared to…
Abstract Number: 707 • 2013 ACR/ARHP Annual Meeting
Different Location and Extent Of Impaired Perfusion Of The Choroid Plexus In Primary and Secondary Raynaud’s Phenomenon
Francesca Ingegnoli¹, Roberta Gualtierotti², Luisa Pierro³, Elisabetta Miserocchi⁴, Giulio Modorati⁵, Claudia Del turco³, Marco Gagliardi³, Giuseppe Parrinello⁶, Tommaso Schioppo² and Pier Luigi Meroni⁷, ¹Dept. of clinical sciences and community health, Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, ²Dept. of clinical sciences and community health, Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, ³Department of Ophthalmology, Vita-Salute University, San Raffaele Scientific Institute, Milano, Italy, ⁴Department of Ophthalmology, Scientific Institute San Raffaele, University Vita-Salute, Milan, Italy, ⁵San Raffaele Scientific Institute, Ocular immunology and uveitis service, Milano, Italy, ⁶Department of Ophthalmology,, Vita-Salute University, San Raffaele Scientific Institute, Milano, Italy, ⁷Division of Rheumatology, Gaetano Pini Institute, Milano, Italy
Background/Purpose: Raynaud’s phenomenon (RP) is a disorder characterized by systemic vascular dysregulation which has been related with vasospasms and retinal blood flow abnormalities. Nevertheless among…
Abstract Number: 708 • 2013 ACR/ARHP Annual Meeting
Intravenous Immunoglobulin May Be An Effective Therapy In Scleroderma Patients With Refractory Active Diffuse Cutaneous Disease
Corrie Poelman¹, Laura K. Hummers², Fredrick M. Wigley², Cynthia Anderson¹, Francesco Boin² and Ami A. Shah², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: A subset of patients with active diffuse cutaneous scleroderma has refractory disease despite traditional immunosuppressive therapy. In this retrospective observational study, we investigated whether…
Abstract Number: 709 • 2013 ACR/ARHP Annual Meeting
Nilotinib (Tasigna™) In The Treatment Of Early Diffuse Systemic Sclerosis: A Single Group, Open Label Pilot Clinical Trial – One Year Results
Jessica K. Gordon¹, Cynthia Magro², Uzunma Udeh¹, Daniele Lerner¹, Horatio F. Wildman³, Wei-Ti Huang⁴, Mary K. Crow⁵ and Robert F. Spiera¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Dermatopathology, Weill-Cornell Medical Center, New York, NY, ³Dermatology, Weill-Cornell Medical Center, New York, NY, ⁴Biostatistics, Hospital for Special Surgery, New York, NY, ⁵Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Tyrosine kinase inhibitors (TKI) are under investigation for the treatment of diffuse cutaneous Systemic Sclerosis (dcSSc.) Nilotinib is a second-generation TKI which selectively antagonizes c-abl and…
Abstract Number: 710 • 2013 ACR/ARHP Annual Meeting
Interleukin-6 Driven STAT3 Phosphorylation In Circulating Lymphocytes Is Specific For CD4⁺ T Cells In Early Rheumatoid Arthritis
Amy E. Anderson¹, Christine Routledge¹, Philip Mawson², John D. Isaacs³ and Arthur G. Pratt³, ¹Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ²Musculoskeletal Directorate, The Freeman Hospital, Newcastle upon Tyne, United Kingdom, ³Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease, caused by a breakdown in self tolerance. Robust biomarkers are needed which, as well having…
Abstract Number: 711 • 2013 ACR/ARHP Annual Meeting
1,25(OH)₂D₃ Inhibits Th17 Cytokine Production and RORγt Expression Through GATA3/IL4-Dependent and -Independent Mechanisms
Wendy Dankers¹, Jan Piet van Hamburg^2,3, Anne-Marie Mus¹, Patrick S. Asmawidjaja¹, Johannes van Leeuwen⁴, Rudi W. Hendriks⁵, Louis Boon⁶, Edgar Colin⁷ and Erik Lubberts^1,8, ¹Rheumatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ²Rheumatology, Erasmus MC, Rotterdam, Netherlands, ³Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁵Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁶Bioceros, Utrecht, Netherlands, ⁷Department of Rheumatology, ZGT, Almelo, Netherlands, ⁸Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands
Background/Purpose: Vitamin D has suppressive effects on autoimmune diseases, such as rheumatoid arthritis (RA). One important mechanism of disease suppression by vitamin D is inhibition…
Abstract Number: 712 • 2013 ACR/ARHP Annual Meeting
Increased IL-23 Receptor Expression Is Observed On KIR3DL2+ CD4+ T Cells In Ankylosing Spondylitis and Correlates With IL-23R Polymorphisms
A. Ridley¹, C. Cohen², T. Karaderi², S. Kollnberger³, I. Wong-Baeza³, J. Shaw³, P. Wordsworth³ and P. Bowness³, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, ²Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: T helper 17 (Th17) cells are a subset of pro-inflammatory CD4+ T cells implicated in a number of inflammatory arthritides including the Spondyloarthritides (SpAs). …
Abstract Number: 713 • 2013 ACR/ARHP Annual Meeting
Interferon Regulatory Factor 2 Haploinsufficiency Deteriorates Imiquimod-Induced Psoriasis-Like Skin Inflammation
Takayuki Kimura¹, Makoto Sugaya², Makiko Kawaguchi¹, Sohshi Morimura¹, Hiraku Suga¹ and Shinichi Sato³, ¹Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, ²Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ³Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan
Background/Purpose: Psoriasis is a T-cell-mediated immunological skin disease with a complex pathogenesis where both genetic and environmental factors are involved. Interferon regulatory factor (IRF)-2 is one…
Abstract Number: 714 • 2013 ACR/ARHP Annual Meeting
Combination Blocking Of Interleukin-6 and Interleukin-21 In Experimental Arthritis Inhibits Their Redundant Role In T Helper 17-Driven Joint Pathology
Debbie M. Roeleveld¹, Marije I. Koenders², Renoud J. Marijnissen^1,3, Cheryl L. Nickerson-Nutter⁴, Fons A. van de Loo¹ and Wim B. van den Berg⁵, ¹Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, Netherlands, ⁴Immunology and Autoimmunity, Pfizer, Cambridge, MA, ⁵Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Both IL-6 and IL-21 have been described to drive in vitro Th17 differentiation in the presence of TGF-β. We explored whether also in vivo…
Abstract Number: 716 • 2013 ACR/ARHP Annual Meeting
The Active Metabolite Of Spleen Tyrosine Kinase Inhibitor Fostamatinib Abrogates The T Cell Priming Capacity Of Dendritic Cells
Andrew Platt¹, Ross McQueenie¹, Robert Benson², John Butcher¹, Martin Braddock³, James M. Brewer⁴, Iain B. McInnes¹ and Paul Garside¹, ¹Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ⁴Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Spleen tyrosine kinase (SYK) is a core signaling protein that drives inflammatory responses and is fundamental to the propagation of signals via numerous immune-receptors…
Abstract Number: 717 • 2013 ACR/ARHP Annual Meeting
Patients With Rheumatoid Arthritis Have Impaired Candida Albicans Specific Th17 Responses But Preserved Oral Candida Albicans Protective Immunity
Shrinivas Bishu¹, E. Wern Su², Erich Wikerson³, Donald M. Jones⁴, Kelly A. Reckley⁵, Sarah L. Gaffen³ and Marc C. Levesque⁶, ¹Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, Pittsburgh, PA, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA
Background/Purpose: Rheumatoid arthritis (RA) patients are susceptible to infections, even after controlling for the effects of medications. Recent data suggest an important role for the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].